The global biomarkers market is poised for substantial growth, with a projected value of USD 182.6 billion by the year 2030. According to recent market analysis, the market size for biomarkers was estimated at USD 66.8 billion in 2022, indicating a robust upward trajectory with a Compound Annual Growth Rate (CAGR) of 13.4% during the forecast period from 2023 to 2030.
Biomarkers, measurable indicators of biological processes or disease states, play a crucial role in healthcare and biomedical research by enabling early disease detection, diagnosis, prognosis, treatment monitoring, and therapeutic decision-making. Key factors driving the growth of the biomarkers market include:
Advancements in Omics Technologies: Continuous advancements in omics technologies, including genomics, proteomics, metabolomics, and transcriptomics, are driving the discovery and validation of novel biomarkers for diverse diseases and therapeutic areas, fueling market growth and innovation.
Personalized Medicine and Precision Health Initiatives: The growing emphasis on personalized medicine approaches, precision health initiatives, and targeted therapies is driving demand for biomarkers for patient stratification, treatment selection, and monitoring of therapeutic responses, driving market expansion across oncology, cardiovascular diseases, neurology, and other therapeutic areas.
Rising Incidence of Chronic Diseases: The increasing prevalence of chronic diseases, such as cancer, cardiovascular diseases, diabetes, and neurological disorders, is driving demand for biomarkers for disease risk assessment, early detection, and disease progression monitoring, driving market growth and adoption across healthcare settings.
Drug Development and Clinical Trials: Biomarkers play a critical role in drug development and clinical trials by facilitating patient selection, treatment response assessment, and safety monitoring, thereby accelerating drug development timelines, reducing development costs, and improving clinical trial success rates, driving demand for biomarker services and solutions.
Technological Advancements in Biomarker Assays: Continuous advancements in biomarker assay technologies, including immunoassays, molecular diagnostics, next-generation sequencing (NGS), and liquid biopsy technologies, are driving improvements in biomarker sensitivity, specificity, and multiplexing capabilities, expanding applications across translational research, diagnostics, and companion diagnostics.
Regulatory Support and Biomarker Qualification: Increasing regulatory support for biomarker qualification and validation, as well as initiatives such as the FDA's Biomarker Qualification Program and the European Medicines Agency's (EMA) qualification of novel biomarkers, are driving confidence in biomarker-based diagnostics and therapeutic development, driving market growth and adoption.
KEY SEGMENTS
By Product
· Consumables
· Services
· Software
By Type
· Safety Biomarkers
· Efficacy Biomarkers
· Predictive Biomarkers
· Surrogate Biomarkers
· Pharmacodynamics Biomarkers
· Prognostic Biomarkers
· Validation Biomarkers
By Application
· Diagnostics
· Drug Discovery & Development
· Personalized Medicine
· Disease Risk Assessment
· Other Applications
By Disease Indication
· Cancer
· Infectious Diseases
· Immune Disorders
· Neurological Disorders
· Cardiovascular Disorders
· Other Disease Indications
The major key players are F. Hoffmann-La Roche Ltd., Abbott, Epigenomics AG, General Electric, Johnson & Johnson Services, Inc., Thermo Fisher Scientific Inc., Bio-Rad Laboratories, Inc., Siemens Healthcare GmbH, QIAGEN and others.
As the global healthcare industry continues to embrace biomarker-driven approaches for disease management, drug development, and personalized medicine, the biomarkers market is expected to witness sustained growth, driven by technological innovation, clinical adoption, and expanding applications across diverse therapeutic areas and healthcare domains.
Other Reports You May Like:
Orthopedic Devices Market Size
About US:
SNS Insider has been a leader in data and analytics globally with its authentic consumer and market insights. The trust of our clients and business partners has always been at the center of who we are as a company. We are a business that leads the industry in innovation, and to support the success of our clients, our highly skilled engineers, consultants, and data scientists have consistently pushed the limits of the industry with innovative methodology and measuring technologies.
We assist our clients to anticipate industrial, economic, and consumer trends to drive disruptive change by fusing global experience with local information from experts throughout the world. We bring context to strategic and tactical data by bridging approaches based on data science and field research, assisting you in addressing your most pressing problems and spotting possibilities.
Contact Us:
Akash Anand – Head of Business Development & Strategy,
Phone: +1-415-230-0044 (US) | +91-7798602273 (IND),
Website: https://www.snsinsider.com
